Following his 10-year run launching Agios and taking the biotech on to its first drug approval, high-profile biotech vet David Schenkein is going the VC route.
We learned via email this morning that Schenkein is hopping to GV, better known as the venture arm of Google, where he will team up with Krishna Yeshwant as a general partner in charge of the life sciences portfolio.
One of the highest profile biotech execs in the Cambridge/Boston hub, Schenkein is also a veteran of Genentech from the glory days. He often said at Agios that he started out with a blank sheet of paper. Now he’ll have a whole stack of blank pages to work with.
David Krane, the CEO of GV, says in the email that they’re “thrilled” to have him join up. Bloomberg was first to report the news.
Image: David Schenkein. the jimmy fund via youtube
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 47,300+ biopharma pros who read Endpoints News by email every day.Free Subscription